Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells.

Autor: Clevenger AJ; Texas A&M University, College Station, United States., Collier CA; Texas A&M University, College Station, United States., Gorley JPM; Texas A&M University, United States., Colijn S; Washington University in St. Louis, United States., McFarlin MK; Texas A&M University, United States., Solberg SC; Texas A&M University, College Station, United States., Kopetz ES; University of Texas MD Anderson Cancer Center, Houston, TX, United States., Stratman AN; Washington University in St. Louis, United States., Raghavan SA; Texas A&M University, College Station, TX, United States.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2024 Nov 01. Date of Electronic Publication: 2024 Nov 01.

Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy.

Autor: Abu-Sbeih H; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Internal Medicine, The University of Missouri, Kansas City, Missouri, USA., Szafron D; Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA., Elkafrawy AA; Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, Ohio, USA., Garcia-Rodriguez V; Department of Internal Medicine, The University of Texas Health Science Center, Houston, Texas, USA., Ma W; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Xu A; Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA., Khurana S; Department of Internal Medicine, The University of Texas Health Science Center, Houston, Texas, USA., Numan L; Department of Internal Medicine, The University of Missouri, Kansas City, Missouri, USA., Chen E; Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA., Goldstein R; Department of Internal Medicine, The University of Texas Health Science Center, Houston, Texas, USA., Tsen A; Department of Internal Medicine, The University of Texas Health Science Center, Houston, Texas, USA., Peng Y; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Bioscience, Rice University, Houston, Texas, USA., Blum M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kopetz ES; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ikoma N; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shatila M; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Raju GS; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ross WA; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ge PS; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Coronel E; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang Y; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2022 Oct; Vol. 37 (10), pp. 1983-1990. Date of Electronic Publication: 2022 Jun 30.

Differential Outcomes in Codon 12/13 and Codon 61 NRAS -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS -Mutated Tumors.

Autor: Cleary JM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. jcleary@partners.org., Wang V; Dana-Farber Cancer Institute, Boston, Massachusetts., Heist RS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Kopetz ES; University of Texas MD Anderson Cancer Center, Houston, Texas., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Kapner KS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Li S; Dana-Farber Cancer Institute, Boston, Massachusetts., Gray RJ; Dana-Farber Cancer Institute, Boston, Massachusetts., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Patton DR; Center for Biomedical Informatics and Information Technology, NCI, Bethesda, Maryland., Meric-Bernstam F; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Dillmon MS; Harbin Clinic Medical Oncology and Clinical Research. Rome, Georgia., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hamilton SR; University of Texas MD Anderson Cancer Center, Houston, Texas., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Aguirre AJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., O'Dwyer PJ; University of Pennsylvania, Philadelphia, Pennsylvania., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Arteaga CL; UT Southwestern Medical Center, Dallas, Texas., Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 01; Vol. 27 (11), pp. 2996-3004. Date of Electronic Publication: 2021 Feb 26.

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.

Autor: Liu L; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: lliu3@illumina.com., Toung JM; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Jassowicz AF; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Vijayaraghavan R; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Kang H; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Zhang R; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Kruglyak KM; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Huang HJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Hinoue T; Van Andel Research Institute, Grand Rapids, The University of Texas MD Anderson Cancer Center, Houston, USA., Shen H; Van Andel Research Institute, Grand Rapids, The University of Texas MD Anderson Cancer Center, Houston, USA., Salathia NS; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Bibikova M; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Granger G; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Barnes B; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Shen R; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Gutekunst K; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Lu C; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Eng C; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Moulder SL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Kopetz ES; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Laird PW; Van Andel Research Institute, Grand Rapids, The University of Texas MD Anderson Cancer Center, Houston, USA., Fan JB; Illumina, Inc., San Diego, The University of Texas MD Anderson Cancer Center, Houston, USA., Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: fjanku@mdanderson.org.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2018 Jun 01; Vol. 29 (6), pp. 1445-1453.